METOCLOPRAMIDE

Metoclopramide Adverse Events Reported to the FDA Over Time

How are Metoclopramide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Metoclopramide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Metoclopramide is flagged as the suspect drug causing the adverse event.

Most Common Metoclopramide Adverse Events Reported to the FDA

What are the most common Metoclopramide adverse events reported to the FDA?

Tardive Dyskinesia	27315 (16.81%)
Extrapyramidal Disorder	22833 (14.05%)
Dystonia	14257 (8.77%)
Nervous System Disorder	10716 (6.6%)
Dyskinesia	4596 (2.83%)
Movement Disorder	4496 (2.77%)
Economic Problem	4273 (2.63%)
Pain	3697 (2.28%)
Incorrect Drug Administration Durat...	3454 (2.13%)
Activities Of Daily Living Impaired	3183 (1.96%)
Tremor	2945 (1.81%)
	Show More
Akathisia	2835 (1.74%)
Anxiety	2783 (1.71%)
Multiple Injuries	2660 (1.64%)
Deformity	2507 (1.54%)
Quality Of Life Decreased	2078 (1.28%)
Family Stress	1953 (1.2%)
Emotional Distress	1733 (1.07%)
Fear	1641 (1.01%)
Anhedonia	1589 (.98%)
Unevaluable Event	1447 (.89%)
Emotional Disorder	1393 (.86%)
Restless Legs Syndrome	1176 (.72%)
Mental Disorder	1138 (.7%)
Visual Impairment	1138 (.7%)
Asthenia	962 (.59%)
Injury	953 (.59%)
Depression	790 (.49%)
Parkinsonism	671 (.41%)
Depression Suicidal	668 (.41%)
Drug Interaction	605 (.37%)
Suicidal Ideation	577 (.36%)
Condition Aggravated	526 (.32%)
Metabolic Disorder	500 (.31%)
Neuropathy Peripheral	500 (.31%)
Impaired Work Ability	498 (.31%)
Overdose	469 (.29%)
Chorea	382 (.24%)
Excessive Eye Blinking	357 (.22%)
Nausea	345 (.21%)
Grimacing	331 (.2%)
Vomiting	296 (.18%)
Death	204 (.13%)
Headache	203 (.12%)
Dyspnoea	201 (.12%)
Gait Disturbance	198 (.12%)
Dysphagia	188 (.12%)
Essential Tremor	188 (.12%)
Fall	188 (.12%)
Insomnia	188 (.12%)
Dizziness	187 (.12%)
Convulsion	175 (.11%)
Muscle Spasms	174 (.11%)
Fatigue	171 (.11%)
Hypertension	163 (.1%)
Confusional State	159 (.1%)
Back Pain	156 (.1%)
Muscle Twitching	153 (.09%)
Restlessness	145 (.09%)
Diarrhoea	143 (.09%)
Weight Decreased	142 (.09%)
Speech Disorder	133 (.08%)
Abdominal Pain	130 (.08%)
Gastrooesophageal Reflux Disease	126 (.08%)
Myoclonus	123 (.08%)
Dysarthria	121 (.07%)
Drug Exposure During Pregnancy	119 (.07%)
Agitation	116 (.07%)
Somnolence	116 (.07%)
Dehydration	113 (.07%)
Hypoaesthesia	113 (.07%)
Loss Of Consciousness	111 (.07%)
Hypotension	108 (.07%)
Arthralgia	105 (.06%)
Constipation	105 (.06%)
Disability	105 (.06%)
Feeling Abnormal	103 (.06%)
Pain In Extremity	103 (.06%)
Paraesthesia	103 (.06%)
Pyrexia	103 (.06%)
Hyperhidrosis	102 (.06%)
Nervousness	100 (.06%)
Abdominal Distension	98 (.06%)
Balance Disorder	98 (.06%)
Malaise	98 (.06%)
Bruxism	97 (.06%)
Cardiac Arrest	95 (.06%)
Partner Stress	95 (.06%)
Stereotypy	95 (.06%)
Renal Failure Acute	92 (.06%)
Drug Ineffective	90 (.06%)
Chest Pain	88 (.05%)
Anaemia	83 (.05%)
Neuroleptic Malignant Syndrome	82 (.05%)
Blood Pressure Increased	80 (.05%)
Completed Suicide	80 (.05%)
Impaired Gastric Emptying	77 (.05%)
Tachycardia	77 (.05%)
Urinary Tract Infection	77 (.05%)
Gastritis	76 (.05%)
Abdominal Pain Upper	74 (.05%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Metoclopramide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Metoclopramide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Metoclopramide

What are the most common Metoclopramide adverse events reported to the FDA?

Movement Disorders	80857 (49.76%)
Neurological	14034 (8.64%)
Anxiety Disorders	4766 (2.93%)
Economic And Housing Issues	4333 (2.67%)
Medication Errors	4235 (2.61%)
Injuries	4083 (2.51%)
Lifestyle Issues	3980 (2.45%)
Mood Disorders	3233 (1.99%)
Depressed Mood Disorders	3108 (1.91%)
Investigations, Imaging And Histopa...	2087 (1.28%)
Family Issues	2064 (1.27%)
	Show More
Gastrointestinal Signs	1419 (.87%)
Psychiatric	1256 (.77%)
Vision	1250 (.77%)
Therapeutic And Nontherapeutic Effe...	874 (.54%)
Respiratory	824 (.51%)
Suicidal And Self-injurious Behavio...	730 (.45%)
Muscle	711 (.44%)
Infections - Pathogen Unspecified	608 (.37%)
Epidermal And Dermal Conditions	594 (.37%)
Peripheral Neuropathies	587 (.36%)
Musculoskeletal And Connective Tiss...	580 (.36%)
Gastrointestinal Motility And Defec...	557 (.34%)
Ocular Neuromuscular	538 (.33%)
Metabolism	505 (.31%)
Cardiac Arrhythmias	496 (.31%)
Changes In Physical Activity	395 (.24%)
Joint	350 (.22%)
Cardiac And Vascular Investigations	316 (.19%)
Sleep Disorders	310 (.19%)
Hematology Investigations	295 (.18%)
Mental Impairment	280 (.17%)
Renal Disorders	280 (.17%)
Chemical Injury And Poisoning	269 (.17%)
Electrolyte And Fluid Balance Condi...	269 (.17%)
Hepatic And Hepatobiliary	269 (.17%)
Headaches	264 (.16%)
Seizures	263 (.16%)
Physical Examination Topics	242 (.15%)
Deliria	239 (.15%)
Neuromuscular	222 (.14%)
Urinary Tract Signs	218 (.13%)
Fatal Outcomes	215 (.13%)
Appetite And General Nutritional	213 (.13%)
Metabolic, Nutritional And Blood Ga...	205 (.13%)
Tongue Conditions	181 (.11%)
Allergic Conditions	175 (.11%)
Hepatobiliary	171 (.11%)
Vascular Hypertensive	171 (.11%)
Central Nervous System Vascular	169 (.1%)
Coronary Artery	169 (.1%)
Gastrointestinal Inflammatory Condi...	167 (.1%)
Skin Appendage Conditions	164 (.1%)
Decreased And Nonspecific Blood Pre...	162 (.1%)
Glucose Metabolism Disorders	154 (.09%)
Bacterial Infectious	152 (.09%)
Disturbances In Thinking	138 (.08%)
Anemias Nonhemolytic And Marrow Dep...	134 (.08%)
Bone Disorders	133 (.08%)
Lower Respiratory Tract Disorders	128 (.08%)
Body Temperature Conditions	127 (.08%)
Musculoskeletal And Connective Tiss...	121 (.07%)
Water, Electrolyte And Mineral	120 (.07%)
Bronchial Disorders	118 (.07%)
Renal And Urinary Tract Investigati...	117 (.07%)
Cardiac Disorder Signs	115 (.07%)
Oral Soft Tissue Conditions	108 (.07%)
Bone And Joint Injuries	107 (.07%)
White Blood Cell	106 (.07%)
Product Quality Issues	102 (.06%)
Personality Disorders	101 (.06%)
Upper Respiratory Tract Disorders	100 (.06%)
Neonatal And Perinatal Conditions	99 (.06%)
Procedural And Device Related Injur...	99 (.06%)
Myocardial	98 (.06%)
Psychiatric And Behavioural Symptom...	98 (.06%)
Gastrointestinal Hemorrhages	89 (.05%)
Encephalopathies	86 (.05%)
Vascular	80 (.05%)
Viral Infectious	79 (.05%)
Gastrointestinal Ulceration And Per...	76 (.05%)
Lipid Metabolism	76 (.05%)
Enzyme	71 (.04%)
Salivary Gland Conditions	71 (.04%)
Eye	69 (.04%)
Thyroid Gland	66 (.04%)
Pulmonary Vascular	64 (.04%)
Toxicology And Therapeutic Drug Mon...	63 (.04%)
Aural	61 (.04%)
Inner Ear And Viiith Cranial Nerve	61 (.04%)
Lipid Analyses	61 (.04%)
Cranial Nerve Disorders	59 (.04%)
Gastrointestinal Stenosis And Obstr...	59 (.04%)
Acid-base	57 (.04%)
Arteriosclerosis, Stenosis, Vascula...	57 (.04%)
Gastrointestinal Conditions	56 (.03%)
Heart Failures	56 (.03%)
Fungal Infectious	55 (.03%)
Sleep Disturbances	55 (.03%)
Administration Site Reactions	54 (.03%)
Dental And Gingival Conditions	51 (.03%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Metoclopramide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Metoclopramide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.